title: The effect of nitric oxide on the production of cyclic AMP by a human osteoblast (HOS) cell line stimulated with hydroxyapatite.
abstract: The aim of the present study was to determine the effect of nitric oxide (NO) on the production of cyclic AMP (cAMP) by a human osteoblast cell line (HOS cells) stimulated with hydroxyapatite. Cells were cultured on the HA surfaces with or without the presence of NO donors (SNAP and NAP) for 3 days. The effect of adenylyl cyclase inhibitor (SQ22536), NO scavenger (carboxy PTIO) or endothelial nitric oxide synthase (eNOS) inhibitor (L-NIO), was assessed by adding these to the cultures of HA-stimulated HOS cells with or without the presence of SNAP. Furthermore, HOS cells were pre-treated with anti-human integrin alphaV antibody prior to culturing on HA surfaces with or without the presence of SNAP. The levels of cAMP and cGMP were determined from the 3-day culture supernatants. The results showed that the production of cAMP but not cGMP by HA-stimulated HOS cells was augmented by SNAP. SQ22536 and carboxy PTIO suppressed but L-NIO only partially inhibited the production of cAMP by HA-stimulated HOS cells with or without the presence of exogenous NO. Pre-treatment of the cells with anti-human integrin alphaV antibody suppressed the production of cAMP by HA-stimulated HOS cells with or without the presence of NO. Therefore, the results of the present study suggest that NO may up-regulate the production of cAMP, perhaps, by augmenting adenylyl cyclase activity initiated by the binding between HOS cell-derived integrin alphaV and HA surface.
authors.affiliation: School of Dentistry, AIMST University, Amanjaya Campus, 2 Persiaran Cempaka, Sungai Petani 08000, Kedah Darul Aman, Malaysia. wsosroseno@yahoo.com
authors.forename: Wihaskoro
authors.initials: W
authors.lastname: Sosroseno
authors.forename: Erwan
authors.initials: E
authors.lastname: Sugiatno
authors.forename: Abdul R
authors.initials: AR
authors.lastname: Samsudin
authors.forename: M Fikri
authors.initials: MF
authors.lastname: Ibrahim
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000067956:Adenylyl Cyclase Inhibitors; D000906:Antibodies / Q000494:pharmacology; D002460:Cell Line; D000242:Cyclic AMP / Q000096:biosynthesis*; D006152:Cyclic GMP / Q000096:biosynthesis; D003497:Cyclic N-Oxides / Q000494:pharmacology; D017886:Durapatite / Q000494:pharmacology*; D016166:Free Radical Scavengers / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D039564:Integrin alphaV / Q000276:immunology; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D052250:Nitric Oxide Synthase Type III / Q000037:antagonists & inhibitors; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D026423:S-Nitroso-N-Acetylpenicillamine / Q000494:pharmacology; D013268:Stimulation, Chemical
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D000906:Antibodies; D003497:Cyclic N-Oxides; D016166:Free Radical Scavengers; D007093:Imidazoles; D039564:Integrin alphaV; D020030:Nitric Oxide Donors; C017759:9-(tetrahydro-2-furyl)-adenine; C079391:2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; D009569:Nitric Oxide; C065027:N(G)-iminoethylornithine; D026423:S-Nitroso-N-Acetylpenicillamine; D017886:Durapatite; D000242:Cyclic AMP; D009952:Ornithine; D052250:Nitric Oxide Synthase Type III; D006152:Cyclic GMP; D000225:Adenine